Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 8/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 8/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA4 | P22748 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | DPP4 | P27487 | 4/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.33 |
| ▸ | REN | P00797 | 2/20 | 0.33 |
| ▸ | USP19 | O94966 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4287969 | 0.93 | CA1 (0.40) | HCRTR1HCRTR2CA1CA2CA4 | |
| SCHEMBL4281507 | 0.92 | CA1 (0.35) | HCRTR1HCRTR2CA1CA2CA4 | |
| SCHEMBL4288667 | 0.90 | CA1 (0.39) | HCRTR1HCRTR2CA1CA2CA4 | |
| SCHEMBL4287918 | 0.88 | DPP4 (0.36) | HCRTR1HCRTR2CA1CA2CA4 | |
| SCHEMBL13705355 | 0.85 | CA1 (0.40) | HCRTR1HCRTR2CA1CA2CA4 | |
| Hydrochloric Acid SCHEMBL4286645 | 0.84 | CA1 (0.39) | HCRTR1HCRTR2CA1CA2CA4 | |
| SCHEMBL13705423 | 0.84 | CHRM3 (0.34) | HCRTR1HCRTR2CA1CA2CA4 | |
| SCHEMBL8114846 | 0.84 | CA1 (0.36) | HCRTR1HCRTR2CA1CA2CA4 | |
| SCHEMBL4284834 | 0.82 | CA1 (0.38) | HCRTR1HCRTR2CA1CA2CA4 | |
| SCHEMBL4290981 | 0.81 | CA1 (0.35) | HCRTR1HCRTR2CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | HCRTR1 3147/4885HCRTR2 3136/4885CA1 2275/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | HCRTR1 3147/4885HCRTR2 3136/4885CA1 2275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.